The place of quetiapine extended release in the treatment of mental disorders

作者: Krzysztof Styczeń , Wojciech Datka , Rafał Jaeschke , Katarzyna Drozdowicz , Marcin Siwek

DOI: 10.12740/PP/33909

关键词: Bipolar disorderQuetiapineIntensive care medicinePsychiatryMoodQuality of life (healthcare)AntipsychoticAtypical antipsychoticSchizophreniaMedicineAnxiety

摘要: Summary This article presents a summary of available data on the use quetiapine extended re­ lease (QUE­XR). QUE­XR is an example atypical antipsychotic drug that can be used in single dose, thereby simplifying treatment regimen. From therapeutic standpoint, this issue paramount importance, since approximately 50% patients have adherence issues. Therefore, availability which comfortable administration signifi­ cantly improve outcomes. Due to its antipsychotic, antidepre­ sive, mood stabilizing and anxiolytic efficacy, seems promising with potentially broad spectrum indications (in schizophrenia, bipolar disorder, major depression some anxiety disorders – both acute phase treatment, maintenance treatment). Notably, ameliorate sleep disturbances, it may also patients’ quality life (as suggested by studies). simple dosing regimen QUE­XR, conducting therapy contribute improvement compliance. Yet, primary clinical criterion for selection type formulation should individual preferences patient, knowledge experience treating physician.

参考文章(37)
Didier Meulien, Martin Brecher, Sherry Liu, David Brown, Jean-Pierre Lindenmayer, The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacology Bulletin. ,vol. 41, pp. 11- 35 ,(2008)
Didier Meulien, Sergiy Malyarov, Joseph Peuskens, Ola Svensson, Martin Brecher, Inger Persson, Frank Miller, Jitendra Trivedi, Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients. Psychiatry (Edgmont (Pa. : Township)). ,vol. 4, pp. 34- 50 ,(2007)
Sanjeev Pathak, Sarah Atkinson, Arifulla Khan, Todd Leathers, Fahua She, Irina Mezhebovsky, Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: A randomized, double-blind study Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. ,vol. 26, pp. 3- 18 ,(2013)
Rebecca Ryan, Nancy Santesso, Dianne Lowe, Sophie Hill, Jeremy M Grimshaw, Megan Prictor, Caroline Kaufman, Genevieve Cowie, Michael Taylor, Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database of Systematic Reviews. ,vol. 2014, ,(2014) , 10.1002/14651858.CD007768.PUB3
Maurizio Pompili, Gianluca Serafini, Xenia Gonda, Leo Sher, Paolo Girardi, Zoltan Rihmer, Early onset of action and sleep-improving effect are crucial in decreasing suicide risk: the role of quetiapine XR in the treatment of unipolar and bipolar depression. Rivista Di Psichiatria. ,vol. 47, pp. 489- 497 ,(2012) , 10.1708/1178.13055
Anna M Depping, Katja Komossa, Werner Kissling, Stefan Leucht, Second-generation antipsychotics for anxiety disorders. Cochrane Database of Systematic Reviews. ,(2010) , 10.1002/14651858.CD008120.PUB2
Gin S Malhi, Danielle M Bargh, Roger McIntyre, Michael Gitlin, Mark A Frye, Michael Bauer, Michael Berk, Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder Bipolar Disorders. ,vol. 14, pp. 1- 21 ,(2012) , 10.1111/J.1399-5618.2012.00989.X
Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, Ayal Schaffer, Serge Beaulieu, Martin Alda, Claire O’Donovan, Glenda MacQueen, Roger S McIntyre, Verinder Sharma, Arun Ravindran, L Trevor Young, Roumen Milev, David J Bond, Benicio N Frey, Benjamin I Goldstein, Beny Lafer, Boris Birmaher, Kyooseob Ha, Willem A Nolen, Michael Berk, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders. ,vol. 15, pp. 1- 44 ,(2013) , 10.1111/BDI.12025
Joseph Peuskens, Jitendra K. Trivedi, Martin Brecher, Frank Miller, Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study International Clinical Psychopharmacology. ,vol. 25, pp. 183- 187 ,(2010) , 10.1097/YIC.0B013E328337789B